Range
- - -
Vol / Avg.
-/637.7K
Div / Yield
-
52 Wk
18.01 - 53.73
Mkt Cap
627M
Payout Ratio
-
Open
-
P/E
-
EPS
-3.5
Shares
28.2M
Outstanding
28.2M
Total Float
20M
Benzinga - Jun 2, 2021, 3:00PM
Benzinga - May 17, 2021, 9:14AM
Benzinga - May 5, 2021, 3:38PM
Benzinga - May 5, 2021, 9:23AM
Benzinga - May 5, 2021, 9:14AM
Benzinga - May 5, 2021, 8:17AM
Benzinga - May 5, 2021, 7:36AM
Benzinga - May 5, 2021, 7:16AM
Benzinga - May 5, 2021, 6:45AM
Benzinga - May 4, 2021, 5:02PM
Benzinga - May 4, 2021, 4:16PM
Benzinga - Apr 27, 2021, 8:10AM
Benzinga - Apr 26, 2021, 4:14PM
Benzinga - Apr 5, 2021, 3:57PM
Benzinga - Mar 17, 2021, 4:09PM
load more
Sector: Health Care.Industry: Biotechnology
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-09
REV
Q1 2021Est.ActualSurprise
EPS-2.520-3.500 -0.9800
REV26.120M7.978M-18.142M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
ESPREsperion Therapeutics0%627M

Esperion Therapeutics Frequently Asked Questions

Q

How do I buy Esperion Therapeutics (ESPR) stock?

A

You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Esperion Therapeutics's (ESPR) competitors?

A

Other companies in Esperion Therapeutics’s space includes: Orchard Therapeutics (NASDAQ:ORTX), KalVista Pharmaceuticals (NASDAQ:KALV), 4D Molecular Therapeutics (NASDAQ:FDMT), Chinook Therapeutics (NASDAQ:KDNY) and Eagle Pharmaceuticals (NASDAQ:EGRX).

Q

What is the target price for Esperion Therapeutics (ESPR) stock?

A

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by Credit Suisse on May 5, 2021. The analyst firm set a price target for 36.00 expecting ESPR to rise to within 12 months (a possible 61.87% upside). 14 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Esperion Therapeutics (ESPR)?

A

The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $22.24 last updated Wed Jun 23 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Esperion Therapeutics (ESPR) pay a dividend?

A

There are no upcoming dividends for Esperion Therapeutics.

Q

When is Esperion Therapeutics (NASDAQ:ESPR) reporting earnings?

A
Esperion Therapeutics’s Q2 earnings are confirmed for after-market on August 9, 2021.
Q

Is Esperion Therapeutics (ESPR) going to split?

A

There is no upcoming split for Esperion Therapeutics.

Q

What sector and industry does Esperion Therapeutics (ESPR) operate in?

A

Esperion Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.